Showing 1271-1280 of 1616 results for "".
- AcuFocus Receives FDA Approval for the IC-8 Apthera IOL, the First and Only Small Aperture Lenshttps://modernod.com/news/acufocus-announces-fda-approval-for-the-ic-8-apthera-iol-the-first-and-only-small-aperture-lens-for-cataract-surgery/2480986/AcuFocus has received FDA approval for its IC-8 Apthera IOL, the first and only non-toric extended depth-of-focus IOL approved for the 82% of cataract patients who have as much as 1.5 diopters (D) of corneal astigmatism.2 “We are delighted to receive
- Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous Anti-VEGF Wet AMD and DME Candidatehttps://modernod.com/news/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate/2480829/Ashvattha Therapeutics announced the presentation of safety data from a phase 1 study of its lead candidate D-4517.2, a VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Amydis Has Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALShttps://modernod.com/news/amydis-has-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/2480493/Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients. The FDA agreed with the overall d
- CATS Tonometer Receives FDA Clearance for Disposable Tonometer Prismhttps://modernod.com/news/cats-tonometer-receives-fda-clearance-for-disposable-tonometer-prism/2479364/The CATS-D Disposable Prism, designed to deliver improved IOP measurement accuracy using a sterile, disposable tip replacement for the Goldmann Tonometer, received FDA clearance and will be available for sale in the fall of 2021. “The CATS Tonometer Prism is designed to provide more accura
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d